Family 3. Selectable marker for development of vectors and transformation systems in plants

The patents of this family are directed to expression vectors for plant transformation containing chimeric genes that comprise a hpt gene. The hpt gene, also noted as an aphIV gene, serves as the basis for the selection of transformed plant cells.

The chimeric genes of the claimed invention contain from 5' to 3' direction:
a) a plant-expressible promoter sequence;
b) an aphIV gene which encodes a hygromycin phosphotransferase enzyme (US 5668298) or
a functional portion of it (US 6048730); and
c) a terminator signal sequence.

The US patent 5668298 claims a particular plasmid, pCEL40, which contains the promoter and the first 11 amino acids of the octopine synthase (OCS) gene of Agrobacterium Ti plasmid fused to an aphIV gene.

The independent claim of the European patent of this family is broader than in the United States patents. The components of the chimeric gene are not spelled out with the exception of "a coding region that confers hygromycin resistance on the plant cell".

Country	Granted Patent No.	Filing Date	Issue date
Patents members of Family 3
Europe*	EP 186425 B1	December 18, 1985	September 30, 1992
Japan	JP 2815837 B2 JP 3090926 B2	December 28, 1995 December 20, 1985	October 27, 1998 September 25, 2000
United States	US 5668298 US 6048730✝	June 7, 1995 September 19, 1990	September 16, 1997** April 11, 2000
* The European patent was converted to a national patent in Belgium (BE), France (FR), Germany (DE), Great Britain (GB), Italy (IT); Liechtenstein (LI); Luxemburg (LU); Netherlands (NL), Sweden (SE) and Switzerland (CH). There is a related patent application pending in Denmark. Patent term of both United States patents is 17 years from the date of issuance. ✝This United States patent was filed by and directly granted to Novartis**. To view or download the patents as PDF files, click on EP 186425 B1 (1.3 kb), US 5668298 (1.0 kb) and US 6048730 ( 0.9 kb).

Thus, in Europe, any chimeric gene for plant transformation conferring resistance to hygromycin is possibly covered by the patented invention. Although, the United States patents are a bit more specific with respect to the comprising elements of the chimeric gene, the chimeric construct is described in such generic terms that it practicably does not leave much freedom to operate for other constructs for plant transformation having an aphIV gene without infringing the patents.

View Independent Claims

The information contained in this page was believed to be correct at the time it was collated. New patents and patent applications, altered status of patents, and case law may have resulted in changes in the landscape. CAMBIA makes no warranty that it is correct or up to date at this time and accepts no liability for any use that might be made of it. Corrections or updates to the information are welcome. Please send an email to info@bios.net.

Comments (0)

Previous Next

CAMBIA Login